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Sendai virus C protein (SeV C) has been reported to counteract the antiviral activities of interferons (IFNs) by inhibiting the
expression of IFN-stimulated gene products. In SeV C-expressing cells, formation of an active ISGF3 complex and
translocation of STAT1 into the nucleus were not observed. STAT1 was continuously phosphorylated at tyrosine 701 by IFN
signaling; however, its serine phosphorylation was suppressed. In addition, tyrosine-phosphorylated STAT1 grew to form
abnormally huge complexes. These findings suggest that the counteraction of IFN in SeV C-expressing cells is caused byT1. ©Introduction. Interferon (IFN) treatment causes cells to
enter an antiviral state through induction of IFN-stimu-
lated gene (ISG) products. It is well known that following
the binding of IFN-/ to specific receptors, the receptor-
associated tyrosine kinases, JAK-1 and Tyk-2, phosphor-
ylate transcription factors STAT1 and STAT2. The het-
erodimerized STAT1 and STAT2 associate with ISG factor
3 (ISGF3)- (p48), forming ISGF3, and then bind to IFN-
stimulated response elements for transcription of ISGs.
Recently, many viral products have been reported to
counteract IFN action by inhibiting the IFN-signaling
pathway via STAT1 (2, 3, 12, 13, 23). It was reported that
Sendai virus (SeV) C protein blocks IFN signaling by
inhibiting formation of an active ISGF3 complex which is
able to induce the expression of ISG proteins (4, 5, 7–9,
10, 11, 18, 22). We report here that SeV C-expressing
HeLa cells circumvented IFN-stimulated antiviral activity
through abnormal phosphorylation and dephosphoryla-
tion of the STAT1 molecule.
Results. Translocation to nucleus and DNA binding of
ISGF3 complex. We reported and confirmed that SeV
C-expressing cells were completely insensitive to the
three types of IFN even if treated with high (10000 IU)
doses (10). In addition, we observed that in SeV C-
1 To whom correspondence and reprint requests should be ad-
dressed at the Department of Viral Diseases and Vaccine Control,
National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimu-205expressing cells, the IFN--stimulated induction of ISG
products (STAT1, STAT2, p48, PKR, and 2,5-oligoadeny-
late synthetases) that was observed in parent cells was
markedly suppressed.
Next, we examined the early process of IFN signaling
before induction of ISG products. It is known that STAT1
forms an ISGF3 complex with STAT2 and p48 and is
translocated to the nucleus before expression of ISG
products. As ISG products were not induced in SeV
C-expressing cells, we examined by indirect immunoflu-
orescence whether STAT1 was translocated to the nu-
cleus in SeV C-expressing cells. As shown in Fig. 1, in
parent HeLa cells, STAT1 was translocated from the
cytoplasm to nucleus after treatment with IFN- (5000 IU)
for 60 min. In contrast, in SeV C-expressing cells, STAT1
was not translocated to the nucleus under the same
conditions. Thus, it was suggested that normal, func-
tional ISGF3 complexes cannot be formed in SeV C-
expressing cells.
Then, we examined whether the ISGF3 complex,
which can bind to a 32P-labeled probe for IRS (ISG15),
was formed, using an electrophoretic mobility shift assay
(EMSA) (Fig. 2). Cells were extracted at 0 h (lanes 1 and
4) or at 4 h (lanes 2, 3, and 5) after treatment with IFN-
(1000 IU). In parent HeLa cells (lane 2), IFN treatment
resulted in formation of an ISGF3 complex, the DNA
binding activity of which was blocked by anti-ISGF3
(p48) (lane 3), while no ISGF3 complex was detected in
SeV C-expressing cells (lane 5). The specific band butdisordered phosphorylation and dephosphorylation of STA
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indicated that the IFN-induced ISGF3 complex was not
formed in SeV C-expressing cells.
Phosphorylation Time Course of STAT1. Next, we fo-
cused on the phosphorylation of STAT1, which is consid-
ered to occur before ISGF3 complex formation. Then we
examined the time course of the phosphorylation of
STAT1 at tyrosine 701 and at serine 727 after treatment
with IFN- (3000 IU) in parent and SeV C-expressing
cells. As shown in Fig. 3A, in parent HeLa cells, tyrosine-
phosphorylated STAT1 (pY-STAT1) increased within 5 min
of IFN treatment, was maintained at high levels for 15–30
min, and then decreased. The phosphorylation level was
very low at 24 h after IFN treatment, despite an increase
in STAT1 protein. On the contrary, in SeV C-expressing
cells, STAT1 that had already been phosphorylated just
prior to IFN treatment continued to phosphorylate for up
to 24 h after IFN treatment. The total amount of STAT1 did
not increase by IFN treatment over 24 h. However, the
IFN-stimulated serine phosphorylation of STAT1 was
suppressed in SeV C-expressing cells, although it was
continuously enhanced in parent cells (Fig. 3B). From
these findings, dephosphorylation of pY-STAT1 and
serine 727 phosphorylation of STAT1 appeared to have
failed in SeV C-expressing cells. The finding of defective
serine phosphorylation of STAT1 agreed with that in
SeV-infected-cells (22).
Detection of STAT1 and STAT2 by Gel Filtration. Since
the phosphorylation of STAT1 was shown to be abnormal
in SeV C-expressing cells (Fig. 3), we next examined the
distributions of STAT1 and STAT2 using gel filtration anal-
ysis. Cell extracts prepared from the parent and SeV
C-expressing cells at the four time points after IFN treat-
ment shown in Fig. 4 were analyzed by gel filtration. The
distributions of STAT1 and STAT2 were analyzed by West-
ern blotting using their specific antibodies. As shown in
Fig. 4, the major peaks of STAT1 did not shift clearly to
larger fractions by IFN treatment in either cell line. The
same result was obtained using another monoclonal
antibody against STAT1 (sc-464; Santa Cruz Biotechnol-
ogy, Inc.). Although the molecular mass of STAT1 is 91
kDa, it was detected in larger fractions. A discrepancy in
size estimation by gel filtration was also reported by
other researchers, suggesting an association of STAT1
with other factors including PKR (16, 18, 20).
In contrast to STAT1, the distribution of STAT2 was
changed markedly by IFN treatment in parent HeLa cells.
In the parent cells, STAT2 was mainly detected as a
monomer in fraction 14–15, at time 0, and it shifted to
fraction 11–15 at 1–4 h after IFN treatment, showing
complex formation (possibly ISGF3). After 24 h, STAT2
was detected as a monomer again. In SeV C-expressing
cells, however, distribution of STAT2 did not change no-
tably at any time after IFN treatment. This finding also
indicates that IFN-stimulated ISGF3 complexes were not
formed by IFN signaling in SeV C-expressing cells.
FIG. 1. Demonstration of translocation of STAT1 to the nucleus in
parent and SeV C-expressing HeLa cells by indirect fluorescence
analysis as described under Materials and Methods.
FIG. 2. Detection of ISGF3 complex formation. Cell extracts were
prepared with lysis buffer (without DTT) and subjected to EMSA.
FIG. 3. Time course of IFN--stimulated phosphorylation of STAT1.
The cell extracts were prepared at the indicated times from the parent
and SeV C-expressing HeLa cells treated with 3000 IU IFN-. The
phosphorylation at tyrosine 701 (A) and at serine 727 (B) of STAT1 was
analyzed by Western blotting using each specific antibody.
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Distribution of pY-STAT1. We examined the distribution
of pY-STAT1 in the same fractions obtained from the gel
filtration as shown in Fig. 5. In parent cells (Fig. 5),
pY-STAT1 was not detected at time 0, but it became
detectable in fraction 14–15 at 1–4 h after IFN treatment,
indicating ISGF3 complex formation. At 24 h after IFN
treatment, the number of complexes was decreased
markedly. In parent cells, STAT1 as a mass did not show
a shift to larger fractions after IFN treatment; however,
pY-STAT1 clearly showed the same distribution as STAT2
(compare Figs. 4 and 5), indicating complex formation of
those proteins. These findings may be explained by the
small amount of pY-STAT1 in the total mass of STAT1. In
SeV C-expressing cells, a small amount of STAT1 is
present as a monomer of pY-STAT1 in fraction 17 even at
time 0 after IFN treatment. The pY-STAT1 became detect-
able in fractions higher than fraction 14 at 1 h, and it
accumulated steadily as abnormally huge complexes
over 600 kDa without any decay in IFN-treated SeV
C-expressing cells. This finding suggests that both the
formation of normal ISGF3 complexes and the dephos-
phorylation of pY-STAT1 were inhibited in SeV C-express-
ing cells.
Discussion. In SeV-infected cells, it was reported that
the level of STAT1 was not increased by IFN treatment
and that either tyrosine 701 or serine 727 phosphoryla-
tion in response to IFN was altered and the formation of
the ISGF3 complex was blocked (11, 22). We and another
group found that C, C, Y1, and Y2 proteins, which are the
P/V/C genome products of SeV, inhibit the establishment
of an IFN-inducible antiviral state (8, 10). In this report,
we described the findings of the IFN-stimulated tyrosine
701 and serine 727 phosphorylation processes of STAT1.
Recently it was reported that viral VH1 (phosphatase of
vaccinia virus) blocked IFN- signal transduction by re-
versing STAT1 activation through the enhancement of
enzyme-dependent dephosphorylation (14). Many stud-
ies were published reporting that negative regulation
was controlled by the dephosphorylation of STATs.
Among them, isolation of a family of cytokine-inducible
signal inhibitors was involved. Proteins named SOCS
can directly bind to JAKs and inhibit the tyrosine kinase
activity (6, 15, 17). More recently, another inhibitor, PIAS
protein, was identified. PIAS blocks the DNA binding
activity of STAT1 and inhibits gene activation (1). Recently
Shp-2 tyrosine phosphatase was reported to be a nega-
tive regulator of the Jak/STAT pathway (21).
Our result indicating the failure of active ISGF3 com-
plex formation in SeV C-expressing cells (Fig. 2) supports
previous findings on SeV-infected cells (11, 18, 22).
We observed the formation and growth of abnormally
huge complexes of pY-STAT1 in SeV C-expressing cells.
In addition, our preliminary data (data not shown) sug-
gested the association of SeV C protein with STAT1 as
has been previously reported (18). Their report also indi-
cated the huge complex formation of STAT1 in SeV-
infected cells. However, we could not demonstrate the
association of SeV C proteins in fractions of the huge
complexes.
FIG. 4. Distributions of STAT1 and STAT2 in gel filtration. Total cell extracts prepared with TNE buffer from 2 108 parent or SeV C-expressing HeLa
cells at the indicated times after IFN treatment were subjected to gel filtration. Fractions of 1 ml were collected at a flow rate of 1 ml/min and analyzed
for STAT1 and STAT2 by Western blotting with the respective antibodies.
FIG. 5. Gel filtration of pY-STAT1 by Superose 6HR. Western blot
analysis was performed for pY-STAT1 using the same fractions shown
in Fig. 4.
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As the activities of STAT signaling are dependent on
tyrosine phosphorylation, the precise recognition and
dephosphorylation of STATs by phosphatases is ex-
pected to be crucial for gene regulation.
Here, although we showed only IFN- (type 1) recep-
tor-mediated signals, IFN- receptor-mediated homo-
dimer formation of STAT1 is likely also influenced in
SeV C-expressing cells. Further studies on type I (/)
and type II () IFN-stimulated signal transductions in
terms of phosphorylation-related responses in these
cells remain to be done.
Materials and Methods. Cells and interferon. A stable
SeV C-expressing HeLa cell line that was established as
described previously (10) and parent HeLa cells were
cultured in Dulbecco’s modified Eagle’s medium with 5%
fetal bovine serum. The IFN- used in this study was
Namalwa cell-derived natural IFN- (Sumiferon) (purified
product 1  108 IU/mg).
Immunoblotting. Cells were harvested by gathering
with a scraper and were disrupted in RIPA buffer con-
taining a protease and phosphatase inhibitor cocktail
(Sigma, Saint Louis, MO). After portions of cell lysate
were subjected to 10% SDS–PAGE, Western blotting
analysis was performed. For detection of STAT1 and
STAT2, antibodies (sc-346 and sc-476, respectively) were
purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Anti-tyrosine-phosphorylated STAT1 (No.
9171S) and anti-serine-phosphorylated STAT1 (No. 06-
802) were purchased from Cell Signaling Technology
(Beverly, MA) and from Upstate Biotechnology (Lake
Placid, NY), respectively. Detection of proteins was per-
formed using LAS-1000 Plus (Fuji Film Co., Tokyo, Japan)
after treatment with an ECL detection kit (Amersham
Pharmacia Biotech UK Ltd., Buckinghamshire, England).
Indirect Immunofluorescence Analysis. After being
washed and fixed, cells cultured on glass slides (eight-
well glass slide; Nalgene Nunc Int., IL) were treated with
anti-STAT1 antibody (sc-346). As the second antibody,
Alexa 488 goat anti-rabbit IgG conjugate (Molecular
Probes, Inc., Eugene, OR) was used.
Electrophoretic Mobility Shift Assay. The EMSA was
performed using 32P-labeled IRS (ISG15) probe as previ-
ously described (19). Anti-ISGF3 (p48) antibody (sc-
496x) was purchased from Santa Cruz Biotechnology,
Inc.
FPLC Gel Filtration Analysis. The cells were extracted
with TNE buffer containing a protease and phosphatase
inhibitor cocktail (Sigma). Gel filtration was performed
using a Superose 6HR 10/30 (Amersham Pharmacia Bio-
tech, Uppsala, Sweden) equilibrated in buffer contain-
ing 20 mM Tris–HCl (pH 7.4), 200 mM NaCl, and 10%
glycerol.
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